Description
Adipotide | Proapoptotic Adipose-Targeting Peptide — Research Grade
Adipotide is a chimeric peptide composed of an adipose-targeting sequence (CKGGRAKDC) that binds prohibitin on the vasculature of white adipose tissue, linked to a proapoptotic D(KLAKLAK)2 sequence that disrupts mitochondrial membranes upon internalisation. It was developed at MD Anderson Cancer Center.
Mechanism of Action
- Prohibitin targeting — CKGGRAKDC sequence homes to prohibitin expressed on blood vessel walls feeding white adipose depots
- Mitochondrial disruption — D(KLAKLAK)2 domain enters mitochondria and induces apoptosis in targeted endothelial cells
- Adipose vasculature ablation — selectively destroys blood supply to white fat, causing adipocyte death via ischaemia
Research Areas
Adipotide has been studied in obese non-human primates, showing significant visceral and subcutaneous fat reduction with improved insulin sensitivity. Research applications include targeted fat reduction biology and tumour vasculature targeting models.
For Research Use Only. Rainbow Peptide supplies Adipotide exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. R. Kolonin –
Adipotide for our adipose vasculature targeting and ANXA2/prohibitin pathway research. Purity confirmed >98% by HPLC. Apoptosis induction assay in our adipocyte model showed expected selective activity. Excellent COA.
S. Okonkwo –
Rare peptide sourced at high purity. Rainbow Peptide’s Adipotide lot was confirmed >98% by our LC-MS. COA included endotoxin data. Our vascular targeting assay showed expected selectivity for white adipose tissue vasculature.
A. Bjornsen –
Adipotide used in our obesity mechanism research. Purity >98%. COA comprehensive. In vitro adipocyte apoptosis assay was consistent with published data. Good documentation and fast delivery.